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ANALISIS EVOLUSI BERASASKAN BIOINFORMATIK KE ATAS 
STRAIN VIRUS INFLUENZA H1N1 DI ASIA TENGGARA 
 
ABSTRAK 
 
Influenza virus A (H1N1) dikenali sebagai agen penyebab dalam jangkitan 
influenza yang serius di serata dunia. Pada bulan April 2009, wabak penyakit 
influenza muncul buat kali pertama dalam abad 21. Sehingga kini, vaksin dan ubat 
antiviral adalah antara rawatan yang berkesan untuk memerangi jangkitan influenza. 
Oleh itu, kajian evolusi virus A (H1N1) di rantau Asia Tenggara (AT) adalah penting 
untuk lebih memahami tentang kepelbagaian, kemunculan rintangan, dan 
keberkesanan vaksin. Untuk mendapatkan gambaran dalam hal ini, analisis 
filogenetik telah dijalankan ke atas rantaian penuh asid amino daripada 
hemagglutinin (HA), neuraminidase (NA) dan protein matriks 2 (M2) daripada 
influenza virus A (H1N1) dari AT. Berdasarkan kepada analisis filogenetik, edaran 
bersama pada kedua-dua strain bermusim dan strain pandemik telah diperhatikan dan 
dikenalpasti melalui pengasingan rantaian strain kepada dua klad yang berbeza. Hasil 
kajian tersebut telah mendedahkan bahawa klad “A/California/07/2009-like” adalah 
penyebab wabak pandemik yang dominan di rantau AT pada 2009. Di samping itu, 
analisis filogenetik bagi HA, NA dan M2 dengan strain vaksin untuk musim 2009-
2011 adalah berkait rapat dengan purata masing-masing sebanyak 96.5%, 98.1% dan 
96.9% kesamaan jujukan. Perbezaan yang paling ketara merupakan tiga penggantian 
asid amino (P100S, S220T dan I338V) di hampir semua HA manakala dua 
penggantian asid amino (V106I dan N248D) di semua NA daripada virus pandemik 
influenza A (H1N1) di rantau AT. Antara 24 variasi dalam HA, lima telah dilaporkan 
xvi 
 
dari epitop A, B dan D (N142D, S160G, I196V, S202T dan A214T) manakala empat 
daripada jumlah 15 variasi telah ditemui di epitop B dan C (P198S, K217R, S339L 
dan N369K) dalam NA daripada strain influenza yang muncul semasa wabak 
influenza 2010-2011. Mutasi H274Y tidak ketara dalam rantau AT. Perolehan mutasi 
strain influenza ini adalah daripada Thailand dan Singapura. Seterusnya, model 
jangkaan 3D bagi kedua-dua HA dan NA telah dihasilkan dan difahami struktur 
perubahan asid amino yang berlaku dengan merujuk kepada strain vaksin. Skor 
DOPE yang terendah untuk kedua-dua model HA (-53940.43) dan NA (-46962.45) 
telah dipilih dan sejajar dengan verifikasi yang dihasilkan oleh PROCHECK (iaitu 
HA: 91.0% dan NA: 89.2% residu-residu di rantau yang digemari), ERRAT (iaitu 
HA: 74.6% dan NA: 83.6% kawasan dengan lipatan protein yang betul) dan ProSA 
(iaitu skor-z bagi HA: -.9.19 dan NA: -5.21 dan kedua-dua telah didapati berada di 
kawasan tenaga yang munasabah).    
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A BIOINFORMATICS-BASED EVOLUTIONARY ANALYSIS ON 
SOUTHEAST ASIA H1N1 INFLUENZA VIRUS STRAINS  
 
ABSTRACT 
 
Influenza virus A (H1N1) is known to be the causative agent of severe 
influenza infections worldwide. In April 2009, a pandemic outbreak of influenza 
disease had occurred for the first time in 21st century. To date, vaccination and 
antiviral drugs are the only effective treatments to combat influenza infection. Thus, 
understanding the evolution of influenza virus A (H1N1) within Southeast Asia 
(SEA) region is crucial to better understand about the diversification, emergence, 
resistance and the vaccine efficacy. In order to gain insight into the matter, 
phylogenetic analyses were conducted on the full-length amino acid sequences of 
hemagglutinin (HA), neuraminidase (NA) and matrix protein 2 (M2) of influenza 
virus A (H1N1) obtained from SEA. Based on the phylogenetic analysis, co-
circulation of both seasonal and pandemic strains were observed and identified via 
the segregation of sequences into two different clades. The results had revealed that 
sequences clustered in A/California/07/2009-like clade were the dominant influenza 
strains for the 2009 pandemic occurrence in SEA. In addition, phylogenetic analyses 
for HA, NA and M2 showed they were related to the vaccine strains for the 2009-
2011 influenza seasons, with an average of 96.5%, 98.1% and 96.9% sequence 
identity, respectively. The most notable differences are three amino acid substitutions 
(P100S, S220T and I338V) in almost all HA while two amino acid substitutions 
(V106I and N248D) in all NA of influenza A (H1N1) pandemic viruses in SEA. 
Among the 24 variations in HA, five were reported from epitopes A, B and D 
xviii 
 
(N142D, S160G, I196V, S202T and A214T). On the other hand, four out of a total of 
15 variations had been found in epitopes B and C (P198S, K217R, S339L and 
N369K) of NA in influenza strains emerged during 2010-2011 influenza season. 
H274Y mutation was not significantly observed in the viruses in SEA. The influenza 
strains that acquired this mutation were from Thailand and Singapore. Subsequently, 
3D models of both HA and NA were predicted and elucidated structurally for the 
amino acid changes with reference to the vaccine strain. The lowest DOPE scores for 
both HA (-53940.43) and NA (-46962.45) models were chosen and they 
corresponded well with the verifications generated by PROCHECK (i.e. HA: 91.0% 
and NA: 89.2% residues in the most favoured region), ERRAT (i.e. HA: 74.6% and 
NA: 83.6% region with the correct protein folding) and ProSA (i.e. z-scores of HA: -
9.19 and NA: -5.21 and both were found in feasible range of energy).   
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1.0 INTRODUCTION 
 
1.1 Problem Statement 
 
Influenza H1N1 disease is not a new disease to the public around the globe. 
The outbreak of influenza H1N1 disease in March and early April 2009 again 
represented a significant fatal disease of the 21st century since the last pandemic 
outbreak of influenza H1N1 disease in 1918. This influenza disease that was first 
started in Mexico and the United States (USA) (Potdar et al., 2010, Smith et al., 2009) 
achieved a rapid spread in a short time to about 207 countries all around the world, 
including countries in the tropics and infected about 622,482 people worldwide 
resulting more than 7,820 deaths as of November 22, 2009. At the same time, 
Southeast Asia region reported about 738 death cases, which make it the region with 
the second highest number of deaths after Americas (WHO, 2009).  
Due to the rapid spread of novel influenza A virus (H1N1-subtyped), the 
World Health Organisation (WHO) was alarmed and raised the worldwide pandemic 
alert level from Phase 5 to Phase 6 on the 11th June 2009 (Smith et al., 2009). This 
indicated that the infectious disease brought by the novel influenza A virus (H1N1-
subtyped) was underway to be a causative factor for the increased number of 
reported deaths. Its high incidence and high mortality rate as well as lack of effective 
treatments have spurred the researchers to carry out extensive researches in 
discovering the cure for the H1N1 pandemic flu.   
With the tropical climate in the Southeast Asia (SEA) region, the people in 
this region are used to the exposure of being infected with seasonal flu throughout 
the year. Seasonal flu is also commonly known as the non-pandemic flu, whereby the 
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influenza A virus is also the causative agent. It is not a new infection to the people in 
the region, yet many of them have underestimated the fatal consequences brought by 
the influenza virus, especially when the influenza virus has turned into a pandemic 
strain. 
 Of recent years, a lot of studies have been researched on the evolutionary of 
the pandemic outbreak of 2009 H1N1 influenza virus that was first reported in 
Mexico and also the discovery of the potential neuraminidase inhibitors in combating 
the influenza disease. Researchers found that mutation and reassortment caused the 
antigenic drift while antigenic shift in different hosts of influenza virus have led to 
the outbreak of novel influenza A virus strain. Existence of the novel strains 
prompted the researchers into the discovery of potential inhibitors on neuraminidase 
protein as the current existing antiviral drugs, such as oseltamivir, is no longer 
effective for the inhibitory effects, especially for the drug-resistant strains.     
 Among the various strains of influenza viruses from the 2009 influenza 
outbreak discovered in SEA region, the evolutionary relationship among these 
influenza viruses in the region are yet to be studied. It is crucial to get the 
relationship among these viruses elucidated by phylogenetic means in order to guide 
the disease prophylaxis before probing for potential inhibitory compounds on 
hemagglutinin (HA), neuraminidase (NA) and matrix protein 2 (M2). The 
evolutionary findings will be of benefits in monitoring the diversification and 
distribution of the HA, NA and M2 proteins from the influenza A viruses in the 
region.  
Phylogenetic study is the main interest for this research since there is no 
previous study has carried out on the evolutionary relationship of all influenza 
A/H1N1-subtyped viruses in SEA. Examination of a phylogeny allows the 
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determination of the relatedness of a sequence of interest to a group of sequences 
whose three-dimensional (3D) structures have been solved experimentally and their 
functions have already been discovered. Comparatively, protein structure is more 
conserved than the protein sequence. Thus, a 3D protein structure would be more 
informative in the binding affinity studies especially in searching for the potential 
inhibitory compounds.  
However, studies have revealed that M2 protein has mutated rapidly and 
developed resistance to the existing adamantine-based antiviral drugs. Since HA and 
NA proteins of influenza virus are relatively evolving at a slower rate than M2 and 
are yet to be determined experimentally in SEA, both HA and NA are worthwhile 
targets to be modelled to obtain the 3D structures. Hence, structural prediction via 
comparative modelling approach were used in this research to obtain the 3D protein 
structures which can lead to the initiation of the drug discovery and drug design 
processes to combat the influenza disease effectively. 
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1.2 Objectives of the study 
 
The objectives of this study were: 
· to study the evolutionary relationship of the HA, NA, and M2 proteins of 
influenza viruses A (H1N1) in SEA; 
· to investigate the amino acid changes in antigenic determinants for HA, NA 
and M2 proteins of influenza viruses A (H1N1) from SEA in order to 
determine the efficacy of vaccine recommended by the WHO; 
· to investigate if the mutations conferring resistance to oseltamivir and 
adamantane-based antiviral drugs were present in the influenza viruses A 
(H1N1) in the region;  
· to determine the 3D model of both glycoproteins (i.e. HA and NA) of 
influenza virus A (H1N1) from Malaysia (A/Malaysia/2142295/2009).  
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2.0 LITERATURE REVIEW 
 
2.1 Background of influenza viruses 
  
 In general, there are three types of influenza viruses in the Orthomyxoviridae 
family, namely influenza type A, type B and type C (Bouvier and Palese, 2008, 
ElHefnawi et al., 2011, Rendell, 2006).  
 Among the three main types of influenza viruses, influenza A viruses have a 
broad range of ability to infect, humans, birds, pigs and other animals. However, 
birds, pigs and humans are the most common hosts to get infected, with the pigs 
being the intermediate host for the influenza A viruses to be spread between the birds 
and the humans (Brown, 2001, Scholtissek, 1994). Influenza A viruses are further 
characterized on the basis of their surface glycoproteins subtypes, i.e. hemagglutinin 
(HA) and neuraminidase (NA). The ratio of both the studded glycoprotein spikes 
(HA and NA) are approximately 4:1. Besides having two glycoproteins on the 
surface, a smaller number of matrix protein 2 (M2), which are the ion channels found 
integrated through the viruses membrane (Bouvier and Palese, 2008). 
Influenza B viruses have a narrow range of susceptible hosts compared to 
influenza A viruses. These viruses are usually found only in the human population 
infections. Thus far, infections by influenza type B viruses are associated with less 
severe epidemics and have not caused any pandemics (Bouvier and Palese, 2008, 
CDC, 2005). With the aid of electron microscopy, they are indistinguishable from the 
influenza A viruses, through the shape or morphology they are sharing. As with 
influenza A, influenza B viruses have both the HA and NA glycoproteins embedded 
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in the membrane and instead of M2, both NB and BM2 substituted the M2 channel 
of type A viruses in influenza B viruses (Bouvier and Palese, 2008). 
In nature, both influenza A and B viruses envelope a segmented genome 
made up of eight negative-sense single-stranded RNA (as shown in Figure 2.1). 
Segmented genome benefits the influenza virus survivability as the nature of the 
genome is able to increase the recombination of different virus genome. These eight 
single-stranded RNA encode for a total of ten proteins, which are named as 
hemagglutinin (HA), neuraminidase (NA), polymerase basic protein 1 (PB1), 
polymerase basic protein 2 (PB2), polymerase acidic protein (PA), matrix protein 1 
(M1), matrix protein 2 (M2), non-structural protein 1 (NS1), non-structural protein 2 
(NS2) and nucleoprotein (NP)  (Prakash et al., 2011, Vazquez, 2008).   
Similar to type B viruses, influenza C viruses are also commonly found in 
human infection with a much lesser severity. To date, they have not caused any 
epidemics or pandemics (CDC, 2005, Rendell, 2006). For influenza C viruses, they 
have only seven segmented RNA genome and express only a single glycoprotein on 
the influenza membrane, which are structurally diverged from both type A and type 
B influenza. The studded surface glycoprotein is identified as hemagglutinin-
esterase-fusion, which is functionally replacing both the HA and NA glycoproteins 
of influenza A and B viruses (Rosenthal et al., 1998, Vazquez, 2008). Unlike 
influenza A strains, both influenza B and C viruses have yet to be further 
characterized into distinct subtypes according to the WHO system of nomenclature. 
As stated in the WHO memorandum published in 1980, the existing antigenic 
variation among influenza B and C viruses are well established and thus the divison 
into subtypes are not warranted (WHO, 1980). 
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Figure 2.1: The structure of influenza A viruses (Taken from: Vazquez, 2008). 
 
2.1.1 Standard nomenclature for influenza A viruses 
 
According to the WHO, the standard nomenclature for all three types of 
influenza (A, B and C) includes the virus type; species from which it was isolated (if 
non-human); location of virus isolation; isolate number; year of isolation (Bouvier 
and Palese, 2008). In addition, an index describing both the surface glycoproteins 
(HA and NA) subtypes are followed in parentheses in identifying the strains of 
influenza A viruses. For instance, A/Malaysia/820/2009 (H1N1) is a human 
influenza A virus from Malaysia in 2009 with the isolate number of 820, and it has 
both HA and NA of subtype 1 (Bouvier and Palese, 2008, WHO, 1980).  
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2.1.2 Reproductive cycle of influenza A viruses 
 
In nature, the influenza survivability is favoured by their segmented genome. 
Influenza viruses replicate themselves by using the host cellular machinery for the 
synthesis of their genome and the related components (Smith and Helenius, 2004).  
To gain access into a living host, recognition and attachment between the HA 
surface glycoproteins of influenza viruses and the N-acetylneuraminic acid (also 
known as sialic acid) is of prime importance to initiate the infection. Sialic acid is a 
cell receptor with nine-carbon acidic monosaccharide, which is usually seen at the 
terminal end of surface glycoproteins of animal species. As mentioned earlier, pigs 
are being the intermediate host for the influeza A viruses to spread between the 
avians and the humans. The logical explanation for this phenomenon could be the 
presence of both sialic acid receptors (α-2,3 and α-2,6) for avian and human 
respectively in pigs (Brown, 2001, Scholtissek, 1994). 
As shown in Figure 2.2, once the HA is attached to the host sialic acid 
receptor, the influenza virus particles will penetrate into the host by endocytosis. The 
penetrated virions will be released from the endosome when the pH of the 
surrounding environment inside the host is decreased to approximately pH 5.0. At 
the acidic environment, the viral M2 ion channels will be activated and allow the 
influx of protons into the virions. The influx of the protons will bring the acidic 
condition to the virions and thus disrupt the protein-protein interactions. As a 
consequence, the virions will be released into the infected cellular cytoplasm 
(Sidorenko and Reichl, 2004, Sieczkarski and Whittaker, 2002a, Sieczkarski and 
Whittaker, 2002b, Vazquez, 2008) before the uncoated virions being transported into 
the cellular nucleus. Using the host cellular nucleus, these virions are transcribed and 
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translated into all the ten structural proteins respectively (Sidorenko and Reichl, 
2004). 
 
 
Figure 2.2: Reproductive cycle of influenza A viruses (Taken from: Sidorenko 
and Reichl, 2004). 
 
Subsequently, all the transcribed and translated virion components are 
packaged in the host cellular nucleus and transported into the cellular cytoplasm. In 
the cytoplasm, accumulation of the M1 matrix proteins initiates the influenza virus 
budding at the cell membrane (Portela and Digard, 2002). The virus progeny can 
only be released upon the present of sialidase activity from the NA surface 
glycoprotein (Bouvier and Palese, 2008, Vazquez, 2008).  
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2.2 Glycoproteins of influenza A viruses 
 
2.2.1 Hemagglutinin  
 
 Hemagglutinin (HA) is one of the two major glycoproteins that are expressed 
and embedded on the viral membrane. To date, HA exists in a total of 16 
serologically distinct subtypes (designated as H1-H16). However, only three HA 
subtypes (H1, H2, and H3) are found to be the circulating strains in human 
population (Astrahan and Arkin, 2010, Bouvier and Palese, 2008). H5 subtype on the 
other hand has been found to be circulating among the avians (Anwar et al., 2006, 
Cheung et al., 2006).  
Structurally HA is composed as a trimeric protein (as shown in Figure 2.3). 
HA is further subdivided into two structurally distinct regions, where there are a stem 
comprising a triple-stranded coiled-coil of alpha-helices, and a globular head of 
antiparallel beta-sheet being positioned atop the stem. The globular head contains the 
sialic acid receptor binding domain and is surrounded by the predicted variable 
antigenic determinants (Bouvier and Palese, 2008).    
 HA protein is responsible to initiate the attachment of virus to cellular sialic 
acid receptors and subsequently mediating the virus to gain entry into the infected 
cell via fusion of viral and cellular membranes (Astrahan and Arkin, 2010). In 
addition, HA also plays a structural role in budding and particle formation (Furuse et 
al., 2010).  
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Figure 2.3: Diagram of an uncleaved HA monomer in ribbon representation of 
influenza virus A (H1N1). The structure contains the sialic acid receptor-binding site, 
which is surrounded by the 5 predicted antigenic sites (Sa, Sb, Ca1, Ca2, and Cb). As 
shown, the stem is composed of the Helix A and B, and the fusion peptide (Taken 
from: Bouvier and Palese, 2008). 
 
2.2.2 Neuraminidase  
 
 Neuraminidase (NA) being the other major glycoproteins, are expressed on 
the influenza A virus surface (Duvvuri et al., 2009, Webster et al., 1982). Together 
with HA, both HA and NA form the basis in identifying the virus. To date, there are 
a total of nine serologically distinct subtypes (designated as N1-N9) of NA are 
known (Astrahan and Arkin, 2010, Bouvier and Palese, 2008). Across these subtypes, 
N-terminal 
C-terminal 
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only N1 and N2 subtypes of NA are more commonly found to cause an influenza 
infectious disease in human populations thus far (Reid et al., 2000).  
The NA proteins are anchored in the viral membrane as a tetramer, which are 
composed of four identical monomeric structures (as shown in Figure 2.4). Each of 
the NA monomers is structurally divided into four main regions: an N-terminal 
conserved hydrophilic hexapeptide, a hydrophobic segment across the 
transmembrane, a thin stalk which is stabilized by carbohydrate and intermolecular 
disulphide bonds, and the enzymatically and antigenically active “head” which is 
positioned at the top of protein structure (Blok and Air, 1982, Guangxiang et al., 
1993, Reid et al., 2000, Sylte and Suarez, 2009).   
 
 
(a)                                            (b) 
 
Figure 2.4: (a) The NA molecule with its “square boxlike head” consists of 4 
coplanar subunits connected to the “stalk” with a hydrophobic knob at the end. (b) A 
rosette of 6 tetrameric NA molecules which have “heads” of about 4 x 8 nm and 
stalks of about 10 nm (Taken from: Blok and Air, 1982). 
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NA protein serves as an enzyme to remove the terminal sialic acids from both 
the viral and host receptors (Sylte and Suarez, 2009). With this cleavage enzymatic 
functionality, NA facilitates the elution of newly formed viruses during budding 
from host cells to initiate the next infection cycle. Cleaving at the terminal sialic 
acids can also prevent the agglutination of HA proteins to the host sialic acid 
receptors (Blok and Air, 1982, Guangxiang et al., 1993, Reid et al., 2000, Sylte and 
Suarez, 2009).   
                        
2.2.3 Matrix protein 2  
 
 Besides HA and NA, the third type of membrane protein, called matrix 
protein 2 (M2), is abundantly expressed on the plasma membrane of infected cells. 
Structurally M2 is a small integral membrane protein with a total of 97 amino acid 
residues, which forms a pH-gated proton channels in the viral transmembrane 
(Schnell and Chou, 2008, Sansom et al., 1997). M2 protein (as shown in Figure 2.5) 
is composed of 3 domains: a short extracellular N-terminal domain with 24 amino 
acid residues; a transmembrane domain with 19 amino acid residues, and a long 
intracellular C-terminal cytoplasmic domain with 54 amino acid residues (Zhong et 
al., 1998). The ion channel is a homotetrameric membrane protein in its native state 
(Holsinger and Alams, 1991, Sugrue and Hay, 1991) which is stabilized by 
disulphide bridges (Sansom et al., 1997, Zhong et al., 1998).  
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Figure 2.5: Scheme of M2 ion channel. M2 protein has a small N-terminal 
domain (24 residues), transmembrane domain (19 residues), and long C-terminal 
domain (54 residues) (Taken from: Betakova, 2007).  
 
 The M2 protein functions as a gated ion channel in the replicative cycle of 
influenza A virus, which will be activated at low acidic pH. At low acidic pH, it 
enables acidification of the interior of endocytosed virions (Holsinger et al., 1994) 
and thus facilitates the protein-protein interactions between the matrix protein and 
virion components. Thus, M2 protein plays a determining role in regulating virus 
morphogenesis, virus assembly and virus budding (Betakova, 2007, Sansom et al., 
1997).  
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2.3 Influenza pandemics 
 
 Influenza virus A is associated with its deadly infection that could bring the 
sudden increase in the mortality rate. They had been the causative agents for several 
pandemic flu outbreaks, such as the Spanish flu (1918), the Asian flu (1957), the 
Hong Kong flu (1968) and the recent Mexican flu (2009). Of all these pandemics, 
they were informally identified in accordance to their presumed sites of origin 
(Kilbourne, 2006). Back to the 1957 and 1968, around the time of the Asian and 
Hong Kong pandemics, some postulated that the influenza pandemic will recur as 
frequent as every 10-11 years (Gaydos, 2006, Morens and Fauci, 2007). However, 
according to the influenza expert, Edwin Kilbourne, Sr., he concluded that there is no 
predictable cyclicity of the major influenza outbreaks, with all of the occurrences 
differ from one another (Kilbourne, 2006).  
 Historically, the Spanish pandemic (H1N1-subtyped) that occurred in 1918-
1919 was among the most deadly pandemics which had killed about 50-100 million 
people worldwide. Thus far, the outbreak was characterized by its exceptionally high 
mortality in the 20th century, especially among the young adults aged in between 15-
45 years old (Morens and Fauci, 2007, Reid et al., 2000). The lack of a complete 
explanation for the origin of 1918 Spanish pandemic has always been disputed. 
However, according to Kilbourne (2006), epidemiologic-epizootiologic evidence 
strongly suggested that the causative influenza virus of the pandemic was actually 
transmitted from humans to swine rather than the reverse direction. On the other 
hand, Taubenberger and colleagues reported contrary to the previous research group. 
Instead of the 1918 virus arose by gene reassortment between human and animal 
16 
 
virus, they claimed the whole process occurred by genome adaptation (Morens and 
Fauci, 2007, Taubenberger et al., 1997, Taubenberger et al., 2005).   
 After a few decades, another pandemic outbreak of Asian flu occurred in 
1957. When substantial amino acid changes had accumulated in the circulating 
H1N1 influenza virus from the very first pandemic outbreak in 1918, the influenza 
virus was therefore drifted to become a novel emergent of H2N2-subtyped influenza 
virus. The disease achieved a rapid global spread to the public with the exception of 
the elderly people aged 70-year-old and above. The 1957 pandemic had called for the 
different vaccine to respond on the novel HA and NA antigens of H2N2-subtyped 
influenza. Unlike the 1918 pandemic, Asian flu viruses (H2N2-subtyped) emerged 
for only 11 years in the human population before being substituted by the Hong 
Kong flu viruses (H3N2-subtyped) (Kilbourne, 2006).     
 Another novel pandemic Hong Kong flu, of H3N2-subtyped influenza virus 
came into existence in the human population in 1968. This pandemic was named in 
accordance to its site of emergence and it was brought by the H3N2 strain influenza 
viruses that arose by gene reassortment. However, widespread immunity to N2 from 
the past exposure to H2N2 flu had helped to lessen the severity of 1968 pandemic flu.  
It has been estimated that 700,000 people died from this pandemic (Reid et al., 2000). 
Among all the pandemics, only the pandemic Mexican flu happened in the 
21st century. Mexican flu was initiated by the H1N1-subtyped influenza viruses, 
which was similar to the influenza subtype that caused 1918 pandemic. However, the 
2009 outbreak was again announced as the pandemic rather than epidemic due to the 
emergence of the resistant H1N1 strains. Evidence suggested that pandemic flu 
outbreak as the result of genetic reassortment and recombination with different 
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strains of influenza A viruses to produce a novel surface protein, either the HA or 
NA or both happened to be novel antigen variants on the viral surface.  
 
2.4 Evolution of influenza A viruses 
 
The hallmark of influenza viruses is antigenic variation, which they evolve 
continually over time by two different means: antigenic drift and antigenic shift (as 
shown in Figure 2.6). Evolution of the influenza is credited to the mutability of the 
segmented RNA genome and thus contributes to the recurrent annual epidemics of 
the infectious disease. Accumulation of the wide antigenic diversity will cause the 
emergence of novel influenza A viruses in human population that has little immunity 
towards the disease (Hay et al., 2001, McDonald et al., 2007, Morens and Fauci, 
2007). 
 
2.4.1 Antigenic drift 
 
According to Treanor (2004), antigenic drift is explained as a subtler process 
than antigenic shift that accumulates point mutations within the antibody-binding 
sites in the HA or / and NA that abrogate the binding of some antibody. The amino 
acid replacements will result in the viruses cannot be inhibited well by the antibodies 
induced by the previous infectious strains. In addition to mutation, Scholtissek (1994) 
also associated the phenomenon as a selection of influenza variants under the 
selection pressure of the host immunity. It is thus easier for the viruses to intrude on 
a partially immune population. Thus, it is necessary to update the vaccine 
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components consistently to confer maximum immunity to the human populations 
against the circulating strains (McDonald et al., 2007, Plotkin et al., 2002). 
 
2.4.2 Antigenic shift 
 
This phenomenon of amino acid replacements produce a new strain of 
influenza A viruses that totally escape from the host immunity. The mutations are 
mainly found in the epitope regions of the surface glycoproteins (HA and NA). As 
influenza A viruses have a broad range of susceptible host, reassortment and 
recombination of genetic materials from different animal species are commonly 
detected. The resulted changes will thus create novel subtypes that have not been 
present in human viruses. Consequently, the introduction of a novel strain into 
human population is usually a pandemic or a worldwide epidemic that will result in 
hundreds of thousands or millions of influenza-related deaths (Scholtissek, 1994, 
Treanor, 2004).  
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Figure 2.6: Phenomenon of antigenic drift that occurred within the same animal  
species while antigenic shift involved combination of genomes from different animal 
species (Taken from: Turner et al., 2010). 
 
2.5 Anti-influenza therapy 
 
 Influenza continues to be a major threat to people around the globe. Evolution 
by antigenic drift caused the regular recurrence of influenza epidemics and numerous 
scientific studies have revealed that sufficient changes will produce drifted virus to 
reinfect the same host (Carrat and Flahault, 2007). To avoid and recover from the 
infection, influenza vaccine and the use of antiviral agents, respectively, are 
recommended. 
 
 
 
Antigenic drift 
Antigenic shift 
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2.5.1 Influenza vaccine 
 
Vaccine remains the most effective defense for the prophylaxis and 
prevention from influenza infections (Gust et al., 2001). However, due to the regular 
emergence of drifted viruses, a review on the influenza vaccine content is needed 
consistently (McDonald et al., 2007, Plotkin et al., 2002). The strain selection is an 
ongoing and complex process whereby it involves the concerted and coordinated 
efforts from national and international organisations. A year round surveillance of 
new influenza strains is conducted by the Centers for Disease Control and Prevention 
and the WHO (Treanor, 2004). As a result, antigenic mismatch can be avoided and 
maximum vaccine effectiveness can be delivered (Wood, 2002).  
 Anti-HA antibody provides a better protection against the drifted influenza 
variants. They are playing the protective role in shielding the recognition and 
attachment between viral HA and host sialic acid receptors. Thus, the influenza 
infection becomes impossible when the first stage of the viral infection is disturbed 
(Virelizier, 1975).   
However, anti-NA antibody in host is triggered by the vaccine strains and 
they serve to inhibit the release of the progeny virus particles from infected cells. The 
inhibited NA proteins of influenza virus are unable to remove the sialic acid 
receptors attached to the HA and thus causing self-aggregation at the surface of 
infected cells (Bouvier and Palese, 2008, Palese et al., 1974, Webster et al., 1982).  
In a nutshell, antibody against the HA is neutralising and is very protective 
against infection and illness while antibody against the NA serves to mitigate the 
severity of illness (Treanor, 2004). 
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2.5.2 Antiviral agents 
 
The unique replication mechanism of influenza virus has allowed 
investigators to identify a number of potential molecular targets for drug design. 
However, there are only two established antiviral agents that are available in the 
current marketplace. Both types of antiviral agents have two different kinds of 
inhibitory mechanisms, either targeting on M2 ion channel or neuraminidase 
glycoprotein, respectively.  
 
2.5.2(a) M2 ion channel blockers 
  
M2 ion channel is a specific target for anti-influenza drugs amantadine and 
rimantadine (Chizhmakov et al., 1996, Holsinger et al., 1994). Amantadine and 
Rimantadine (as shown in Figure 2.7) are two drugs belong to the Adamantanes 
group (Schnell and Chou, 2008, Zaraket et al., 2010) which has been introduced for 
prophylaxis and treatment of influenza A disease for many years. Both drugs are 
proven inactive against influenza B viruses which lack of the M2 membrane-
spanning proteins (Sansom et al., 1997). 
 
 
Figure 2.7: The structure of M2 ion channel blockers: amantadine (left) and 
rimantadine (right) (Taken from: Astrahan and Arkin, 2010).  
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In designing drugs to exert inhibitory effects on the wild-type M2 (WT-M2) 
ion channel, two mechanisms of action were proposed: the drug that blocks the 
channel by binding at the opening of the pore (Astrahan et al., 2004), and the drug 
that binds firmly to the side chains of H37 in a deeper location of the channel (Pinto 
and Lamb, 2007, Zhong et al., 2000). These proposed mechanisms were 
subsequently proven in the experimental and theoretical studies (Chen et al., 2007, 
Hu et al., 2006, Intharathep et al., 2008, Kass and Arkin, 2005, Laohpongspaisan et 
al., 2009).  
However, studies revealed that their use has been restricted as the adverse 
effects on the intestinal and central nervous systems arose and the emergence of 
resistance towards the drugs (Englund et al., 1998, Hayden et al., 1989, McKimm-
Breschkin et al., 2003). The resistance to these drugs is genetically associated with 
amino acid substitutions at positions L26, V27, A30, S31, G34, L38 and W41 in the 
membrane-spanning domain of the protein (Englund et al., 1998, Holsinger et al., 
1994, Saito et al., 2006). Among these mutations, A30T and S31N are the most 
common mutations for influenza A viruses from Vietnam, Malaysia, Cambodia and 
Thailand in SEA region that confer resistance towards amantadine (Hurt et al., 2007, 
Ilyushina et al., 2005).  
For V27A and S31N mutations, the replacement of valine to alanine had 
caused the widening of channel’s pore size while the latter mutation led to the 
reduction in channel’s pore size. The size of the channel’s pore is associated to the 
changes in the H+ influx (Astrahan and Arkin, 2010). Laohpongspaisan and 
coworkers (2009) had also studied the proton conductance in terms of the water 
density across the channel. However, zero water density was reported associated to 
the L26I mutation while a slight degree of water density was traced in the presence 
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of A30T mutation (Laohpongspaisan et al., 2009). The pH of M2 channel will 
ultimately determine the opening of the channel, of which the protonated H37 
residue and the rotation of W41 side chain to a conformation parallel to the pore’s 
axis will allow the influx of H+ (Betakova, 2007). 
 
2.5.2(b) Neuraminidase inhibitors  
  
 Prior to the existence of both zanamivir and oseltamivir, 2-deoxy-2,3-
didehydro-D-N-acetylneuraminic acid (DANA, as shown in Figure 2.8), an 
unsaturated transition-state sialic acid analog was first designed and synthesized to 
inhibit the NA enzyme activity. However, its inhibitory activity on NA is reported to 
be weak in vitro and vice versa when administered in vivo (McKimm-Breschkin, 
2000). As a result, a review on DANA drug design is demanded in order to produce a 
NA antiviral drug with better inhibitory activity.  
 
 
 
Figure 2.8: Chemical structure of unsaturated sialic acid analog (DANA) (Taken 
from: Varghese et al., 1998). 
 
4’ 
6’ 
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Drug design based on the complex structure of viral NA protein and its cell 
surface receptor (sialic acid), such as zanamivir (GG167) (as shown in Figure 2.9) is 
efficacious for inhibiting the influenza infection. Zanamivir has a different 
conformation than the previous NA inhibitor where the 4’ position on the sugar ring 
of DANA is replaced by a guanidinium group. There are two ways of administration, 
either through oral inhalation or intranasal instillation. High concentration of the 
inhaled drug will be delivered to the respiratory tract (Gubareva et al., 2000), where 
the virus is replicating (McKimm-Breschkin et al., 2003, McKimm-Breschkin, 2000, 
Smith et al., 2001).  
Subsequently, oseltamivir (as shown in Figure 2.9) was developed based on 
the need for antiviral to be efficacious as an orally administered NA inhibitor. 
Instead of a single substitution on the sugar ring in zanamivir, oseltamivir has a 
cyclohexene ring with a substitution of an amino group at the 4’ position in the ring 
and more importantly the glycerol side chain at 6’ position is replaced by a bulky 
hydrophobic pentyl ether group (McKimm-Breschkin et al., 2003, McKimm-
Breschkin, 2000, McKimm-Breschkin et al., 2007). Oseltamivir exists in two forms: 
oseltamivir carboxylate (GS4071) and oseltamivir phosphate (GS4104) (Lew et al., 
2000). Usually, it is taken orally in the form of ethyl ester prodrug oseltamivir 
phosphate, which is subsequently converted by hepatic esterases to the active form of 
oseltamivir, called oseltamivir carboxylate (McKimm-Breschkin et al., 2003, 
McKimm-Breschkin, 2000, Smith et al., 2001). 
 
